Recent News

• 12.12.2025 - Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds
• 12.11.2025 - Enveric Biosciences skyrockets on patent allowance for psychedelic-inspired molecules [Mugglehead Magazine]
• 12.11.2025 - Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds
• 12.09.2025 - Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
• 12.04.2025 - Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”
• 12.03.2025 - The Quiet Race Reshaping Psychedelic Medicine [Meditech Today]
• 12.01.2025 - Healing A Broken Mental Health System: Dr Joseph Tucker of Enveric Biosciences On 5 Things That Can Be Done To Fix Our Broken Mental Health System [Medium]
• 11.26.2025 - Delix Therapeutics Reports Strong Phase Ib Results [Microdose]
• 11.26.2025 - Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates
• 11.14.2025 - Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Recent Filings

• 12.11.2025 - 8-K Current report
• 12.10.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.08.2025 - EFFECT Notice of Effectiveness
• 12.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.05.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 12.05.2025 - S-3/A Registration statement under Securities Act of 1933
• 11.14.2025 - EX-99.1 EX-99.1
• 11.14.2025 - 8-K Current report